Abstract The European Medicines Agency (EMA) played a crucial role in responding to the COVID-19 pandemic by implementing various innovations that facilitated the development and approval of vaccines and treatments. This article analyses some of those innovations on the agency’s operations through literature on innovation in the public sector using a literature review, publications on EU policy along with internal knowledge by the authors. The agency’s innovative approaches such as the establishment of the COVID-19 Emergency Task Force and the effective use of real-world evidence enabled the agency to provide rapid advice to developers and ensure the provision of scientific feedback to the authorities and the public during crisis. The changes implemented led to new legislation allowing long-term effects within the agency. The EMA has emerged from the COVID-19 pandemic strengthened by innovative approaches leading to new legislation enabling an expanded mandate of the agency. To sustain innovation at the EMA, the agency might have to consider a structured and comprehensive approach to innovation, including the importance of fostering an innovation culture within the organization.
Gillini et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: